Faculty Collaboration Database

Medical College of Wisconsin

CTSI Cores Search Research Informatics REDCap

Staley A. Brod MD

Professor

Institution: Medical College of Wisconsin
Department: Neurology
Division: General

Member of the Neuroscience Research Center

Send Message

Request Meeting

Publications (85)

Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease. (Brod SA) J Alzheimers Dis 2021 Nov 21 PMID: 34842189 11/30/2021

A proposal: How to study pro-myelinating proteins in MS. (Brod SA) Autoimmun Rev 2022 Jan;21(1):102924 PMID: 34416371 SCOPUS ID: 2-s2.0-85113134702 08/21/2021

Immune reconstitution therapy in NMOSD. (Brod SA) Mult Scler Relat Disord 2021 Jul;52:102971 PMID: 33992916 SCOPUS ID: 2-s2.0-85105893435 05/17/2021

Plegia to walking: AHSCBMT in severe NMOSD relapse. (Carlisle N, Hari P, Brod S) BMJ Neurol Open 2020;2(2):e000073 PMID: 33681798 PMCID: PMC7903183 SCOPUS ID: 2-s2.0-85105891279 03/09/2021 1 Citation

Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects (Brod SA) Multiple Sclerosis and Related Disorders November 2020;46 SCOPUS ID: 2-s2.0-85092416377 11/01/2020 4 Citations

Plegia to walking: AHSCBMT in severe NMOSD relapse (Nicola Carlisle,1 Parameswaran Hari,2 Staley Brod) BMJ Neurology Open BMJ Neurology Open 2020;2:e000073. doi:10.1136/ bmjno-2020-000073 10/26/2020

Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. (Brod SA) Mult Scler Relat Disord 2020 Nov;46:102538 PMID: 33059216 PMCID: PMC7539063 SCOPUS ID: 2-s2.0-85092416377 10/16/2020 4 Citations

In MS: Immunosuppression is passé. (Brod SA) Mult Scler Relat Disord 2020 May;40:101967 PMID: 32007655 SCOPUS ID: 2-s2.0-85078735778 02/03/2020 7 Citations

Ingested ACTH blocks Th17 production by inhibiting GALT IL-6. (Dittel LJ, Dittel BN, Brod SA) J Neurol Sci 2020 Feb 15;409:116602 PMID: 31812846 SCOPUS ID: 2-s2.0-85075869362 12/10/2019 3 Citations

Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS. (Freedman MS, Brod S, Singer BA, Cohen BA, Hayward B, Dangond F, Coyle PK) J Neurol 2020 Jan;267(1):64-75 PMID: 31559532 PMCID: PMC6954891 SCOPUS ID: 2-s2.0-85074028696 09/29/2019 1 Citation

Clinical and MRI efficacy of sc IFN beta-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS (Freedman, M. S. Brod, S. Singer, B. A. Cohen, B. A. Hayward, B. Dangond, F. Coyle, P. K.) J Neurol 10.1007/s00415-019-09532-5 09/29/2019

Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments. (Brod SA, Lindsey JW, Nelson F) Mult Scler J Exp Transl Clin 2019 Apr-Jun;5(2):2055217319855755 PMID: 31245023 PMCID: PMC6582300 06/28/2019

Myelinating Proteins in MS Are Linked to Volumetric Brain MRI Changes. (Brod SA, Lincoln JA, Nelson F) J Neuroimaging 2019 05;29(3):400-405 PMID: 30748043 SCOPUS ID: 2-s2.0-85061374097 02/13/2019 1 Citation

Ingested (oral) rituximab inhibits EAE. (Brod SA) Cytokine 2016 09;85:177-83 PMID: 27372916 SCOPUS ID: 2-s2.0-85039561776 07/04/2016 4 Citations

Ingested (oral) anti-IL-12/23 inhibits EAE. (Brod SA) J Neurol Sci 2016 Feb 15;361:19-25 PMID: 26810510 SCOPUS ID: 2-s2.0-84958957357 01/27/2016 3 Citations

Ingested (oral) tocilizumab inhibits EAE. (Brod SA, Bauer VL) Cytokine 2014 Aug;68(2):86-93 PMID: 24845797 SCOPUS ID: 2-s2.0-84899838838 05/23/2014 6 Citations

Contrast enhanced MR venography with gadofosveset trisodium: evaluation of the intracranial and extracranial venous system. (Kramer LA, Cohen AM, Hasan KM, Heimbigner JH, Barreto AD, Brod SA, Narayana PA, Wolinsky JS) J Magn Reson Imaging 2014 Sep;40(3):630-40 PMID: 24273083 SCOPUS ID: 2-s2.0-84906084714 11/26/2013 7 Citations

Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessment. (Brod SA, Kramer LA, Cohen AM, Barreto AD, Bui TT, Jemelka JR, Ton K, Lindsey JW, Nelson F, Narayana PA, Wolinsky JS) Mult Scler 2013 Oct;19(11):1499-507 PMID: 23828872 PMCID: PMC3783583 SCOPUS ID: 2-s2.0-84884557750 07/06/2013 8 Citations

Chronic cerebrospinal venous insufficiency: case-control neurosonography results. (Barreto AD, Brod SA, Bui TT, Jemelka JR, Kramer LA, Ton K, Cohen AM, Lindsey JW, Nelson F, Narayana PA, Wolinsky JS) Ann Neurol 2013 Jun;73(6):721-8 PMID: 23418024 PMCID: PMC3657573 SCOPUS ID: 2-s2.0-84881260526 02/19/2013 19 Citations

Ingested (oral) thyrotropin releasing factor (TRH) inhibits EAE. (Brod SA, Bauer V) Cytokine 2013 Jan;61(1):323-8 PMID: 23148993 SCOPUS ID: 2-s2.0-84869865496 11/15/2012 3 Citations

Lack of response to rituximab therapy in patients with neuromyelitis optica: Response to Kim and Kim (Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS) Journal of the Neurological Sciences 15 August 2012;319(1-2):172 SCOPUS ID: 2-s2.0-84862769586 08/15/2012

Ingested (oral) neuropeptide Y inhibits EAE. (Brod SA, Bauer VL) J Neuroimmunol 2012 Sep 15;250(1-2):44-9 PMID: 22703767 SCOPUS ID: 2-s2.0-84864858939 06/19/2012 4 Citations

Variable results after rituximab in neuromyelitis optica. (Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS) J Neurol Sci 2012 Jun 15;317(1-2):103-5 PMID: 22405926 SCOPUS ID: 2-s2.0-84860308411 03/13/2012 53 Citations

Oral ACTH (H.P. Acthar(®)Gel) inhibits IL-1 and IL-17 secretion in humans. (Brod SA, Bauer V, Hood Z) Biomed Pharmacother 2012 Feb;66(1):36-9 PMID: 22244960 SCOPUS ID: 2-s2.0-84856656063 01/17/2012 6 Citations

Ingested (oral) SST inhibits EAE. (Brod SA, Hood ZM) Autoimmunity 2011 Aug;44(5):437-43 PMID: 21244338 SCOPUS ID: 2-s2.0-79960113599 01/20/2011 11 Citations

Ingested (oral) ACTH inhibits EAE. (Brod SA, Hood ZM) J Neuroimmunol 2011 Mar;232(1-2):131-5 PMID: 21081248 SCOPUS ID: 2-s2.0-79952245992 11/18/2010 20 Citations

Ingested Type I Interferon-State of the Art as Treatment for Autoimmunity Part 2. (Brod SA) Pharmaceuticals (Basel) 2010 Apr 14;3(4):1108-1121 PMID: 27713291 PMCID: PMC4034024 SCOPUS ID: 2-s2.0-77952134650 04/14/2010 2 Citations

Effect of ingested interferon-α on β-cell function in children with new-onset type 1 diabetes (Diabetes Care (2009) 32, (1250-1255)) (Rother KI, Brown RJ, Morales MM, Wright E, Duan Z, Campbell C, Harlan DM, Orlander PR, Brod SA, Hardin DS, Popovic J, McEvoy RC) Diabetes Care September 2009;32(9):1751 SCOPUS ID: 2-s2.0-69549129474 09/01/2009

Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. (Rother KI, Brown RJ, Morales MM, Wright E, Duan Z, Campbell C, Hardin DS, Popovic J, McEvoy RC, Harlan DM, Orlander PR, Brod SA) Diabetes Care 2009 Jul;32(7):1250-5 PMID: 19564474 PMCID: PMC2699745 SCOPUS ID: 2-s2.0-67650072951 07/01/2009 35 Citations

Bio-equivalence of IM and SQ H.P. Acthar Gel. (Brod SA, Morales MM) Biomed Pharmacother 2009 May;63(4):251-3 PMID: 18848765 SCOPUS ID: 2-s2.0-64749115455 10/14/2008 7 Citations

Ingested (oral) SIRS peptide 1-21 suppresses type 1 diabetes in NOD mice. (Brod SA, Hood Z) J Interferon Cytokine Res 2008 Jan;28(1):25-30 PMID: 18370869 SCOPUS ID: 2-s2.0-38649142133 03/29/2008 5 Citations

Ingested (oral) alpha-MSH inhibits acute EAE. (Brod SA, Hood ZM) J Neuroimmunol 2008 Jan;193(1-2):106-12 PMID: 18037504 SCOPUS ID: 2-s2.0-37749026839 11/27/2007 19 Citations

Ingested (oral) SIRS peptide 1-21 inhibits acute EAE by inducing Th2-like cytokines. (Brod SA, Hood Z) J Neuroimmunol 2007 Feb;183(1-2):89-95 PMID: 17196668 SCOPUS ID: 2-s2.0-33846783032 01/02/2007 12 Citations

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. (Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS, Copaxone Study Group) Mult Scler 2006 Jun;12(3):309-20 PMID: 16764344 SCOPUS ID: 2-s2.0-33744814611 06/13/2006 119 Citations

Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis. (Brod SA, Nguyen M, Hood Z, Shipley GL) J Interferon Cytokine Res 2006 Mar;26(3):150-5 PMID: 16542137 SCOPUS ID: 2-s2.0-33645419764 03/18/2006 9 Citations

A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. (Mikol D, Lopez-Bresnahan M, Taraskiewicz S, Chang P, Rangnow J, Rebiject Study Group) Mult Scler 2005 Oct;11(5):585-91 PMID: 16193898 SCOPUS ID: 2-s2.0-25844457405 10/01/2005 55 Citations

Ingested type I interferon: a potential treatment for autoimmunity. (Brod SA) J Interferon Cytokine Res 2002 Dec;22(12):1153-66 PMID: 12581487 SCOPUS ID: 2-s2.0-0036975241 02/13/2003 16 Citations

Ingested type I interferon: state of the art as treatment for autoimmunity. (Brod SA) Exp Biol Med (Maywood) 2002 Dec;227(11):981-8 PMID: 12486207 SCOPUS ID: 2-s2.0-0036913590 12/18/2002 5 Citations

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. (CHAMPS Study Group) Neurology 2002 Oct 08;59(7):998-1005 PMID: 12370452 SCOPUS ID: 2-s2.0-0037044262 10/10/2002 83 Citations

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group. Mult Scler 2002 Oct;8(5):405-9 PMID: 12356207 SCOPUS ID: 2-s2.0-18544375281 10/03/2002 12 Citations

Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study. Mult Scler 2002 Aug;8(4):330-8 PMID: 12166504 SCOPUS ID: 2-s2.0-0036690335 08/09/2002 24 Citations

Ingested IFN-alpha preserves residual beta cell function in type 1 diabetes. (Brod SA, Atkinson M, Lavis VR, Brosnan PG, Hardin DS, Orlander PR, Nguyen M, Riley WJ) J Interferon Cytokine Res 2001 Dec;21(12):1021-30 PMID: 11798459 SCOPUS ID: 2-s2.0-0035701950 01/19/2002 20 Citations

Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS. (Brod SA, Lindsey JW, Vriesendorp FS, Ahn C, Henninger E, Narayana PA, Wolinsky JS) Neurology 2001 Sep 11;57(5):845-52 PMID: 11552015 SCOPUS ID: 2-s2.0-0035845612 09/12/2001 26 Citations

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. (Wolinsky JS, Narayana PA, Johnson KP, Multiple Sclerosis Study Group and the MRI Analysis Center) Mult Scler 2001 Feb;7(1):33-41 PMID: 11321192 SCOPUS ID: 2-s2.0-17744367204 04/26/2001 85 Citations

Unregulated inflammation shortens human functional longevity. (Brod SA) Inflamm Res 2000 Nov;49(11):561-70 PMID: 11131295 SCOPUS ID: 2-s2.0-0033695682 12/29/2000 72 Citations

Ingested interferon-α has biological effects in rheumatoid arthritis (Brod SA, Friedman AW, Appleyard J, Warner NB, Henninger EM) International Journal of Immunotherapy 2000;16(3-4):53-58 SCOPUS ID: 2-s2.0-0034457130 12/01/2000 2 Citations

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. (Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS) Mult Scler 2000 Aug;6(4):255-66 PMID: 10962546 SCOPUS ID: 2-s2.0-0033842848 08/30/2000 230 Citations

Ingested interferon-alpha prevents allograft islet transplant rejection. (Brod SA, Katz S, Phan T, Stepkowski S) Transplantation 2000 May 27;69(10):2162-6 PMID: 10852617 SCOPUS ID: 2-s2.0-0034720549 06/14/2000 6 Citations

Adoptive transfer from interferon-alpha-fed mice is associated with inhibition of active experimental autoimmune encephalomyelitis by decreasing recipient tumor necrosis factor-alpha secretion. (Brod SA, Khan M, Nelson LD, Decuir B, Malone M, Henninger E) J Immunother 2000 Mar-Apr;23(2):235-45 PMID: 10746550 SCOPUS ID: 2-s2.0-0034117395 04/04/2000 13 Citations

Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. (Brod SA, Lindsey JW, Wolinsky JS) Ann Neurol 2000 Jan;47(1):127-31 PMID: 10632113 SCOPUS ID: 2-s2.0-0033960042 01/13/2000 49 Citations

Autoimmunity is a type I interferon-deficiency syndrome corrected by ingested type I IFN via the GALT system. (Brod SA) J Interferon Cytokine Res 1999 Aug;19(8):841-52 PMID: 10476927 SCOPUS ID: 2-s2.0-0032856868 09/07/1999 14 Citations

Ingested interferon alpha induces Mx mRNA. (Brod SA, Nelson L, Jin R, Wolinsky JS) Cytokine 1999 Jul;11(7):492-9 PMID: 10419650 SCOPUS ID: 2-s2.0-0033019248 07/27/1999 20 Citations

Ingested interferon alpha suppresses type I diabetes in non-obese diabetic mice. (Brod SA, Malone M, Darcan S, Papolla M, Nelson L) Diabetologia 1998 Oct;41(10):1227-32 PMID: 9794112 SCOPUS ID: 2-s2.0-0031782993 10/30/1998 37 Citations

Hypothesis: multiple sclerosis is a type I interferon deficiency syndrome. (Brod SA) Proc Soc Exp Biol Med 1998 Sep;218(4):278-83 PMID: 9714071 SCOPUS ID: 2-s2.0-0031852204 08/26/1998 8 Citations

Gut response. Therapy with ingested immunomodulatory proteins. (Brod SA) Arch Neurol 1997 Oct;54(10):1300-2 PMID: 9341578 SCOPUS ID: 2-s2.0-0030824070 10/28/1997 12 Citations

Increased in vitro induced CD4+ and CD8+ T cell IFN-gamma and CD4+ T cell IL-10 production in stable relapsing multiple sclerosis. (Brod SA, Nelson LD, Khan M, Wolinsky JS) Int J Neurosci 1997 Aug;90(3-4):187-202 PMID: 9352427 SCOPUS ID: 2-s2.0-0031214297 08/01/1997 17 Citations

IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months. (Brod SA, Nelson LD, Khan M, Wolinsky JS) Int J Neurosci 1997 Jun;90(1-2):135-44 PMID: 9285295 SCOPUS ID: 2-s2.0-0030829048 06/01/1997 12 Citations

Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis. (Brod SA, Kerman RH, Nelson LD, Marshall GD Jr, Henninger EM, Khan M, Jin R, Wolinsky JS) Mult Scler 1997 Feb;3(1):1-7 PMID: 9160341 SCOPUS ID: 2-s2.0-0030946161 02/01/1997 42 Citations

Effects of oral administration of type i interferons on experimental autoimmune encephalomyelitis (Brod SA) Interferon Therapy of Multiple Sclerosis 1 January 1997:245-286 SCOPUS ID: 2-s2.0-0343329932 01/01/1997 6 Citations

Ingested IFN-α has biological effects in humans (Brod SA, Nelson L, Wolinskv JS) FASEB Journal 1996;10(6) SCOPUS ID: 2-s2.0-33748916467 12/01/1996

Multiple sclerosis: clinical presentation, diagnosis and treatment. (Brod SA, Lindsey JW, Wolinsky JS) Am Fam Physician 1996 Sep 15;54(4):1301-6, 1309-11 PMID: 8816574 SCOPUS ID: 2-s2.0-0029830737 09/15/1996 11 Citations

Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. (Brod SA, Marshall GD Jr, Henninger EM, Sriram S, Khan M, Wolinsky JS) Neurology 1996 Jun;46(6):1633-8 PMID: 8649562 SCOPUS ID: 2-s2.0-0029950889 06/01/1996 122 Citations

Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. (Brod SA, Khan M) J Autoimmun 1996 Feb;9(1):11-20 PMID: 8845048 SCOPUS ID: 2-s2.0-0029985565 02/01/1996 63 Citations

Oral administration of type I interferon modulates the course of experimental allergic neuritis. (Vriesendorp FJ, Flynn RE, Khan M, Pappolla MA, Brod SA) Autoimmunity 1996;24(3):157-65 PMID: 9020408 SCOPUS ID: 2-s2.0-0030454489 01/01/1996 23 Citations

Decreased CD3-mediated interferon-gamma production in relapsing-remitting multiple sclerosis. (Brod SA, Khan M, Bright J, Sriram S, Marshall GD Jr, Henninger EM, Kerman RH, Wolinsky JS) Ann Neurol 1995 Apr;37(4):546-9 PMID: 7717692 SCOPUS ID: 2-s2.0-0028987125 04/01/1995 17 Citations

Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. (Brod SA, Khan M, Kerman RH, Pappolla M) J Neuroimmunol 1995 Apr;58(1):61-9 PMID: 7537281 SCOPUS ID: 2-s2.0-0028903315 04/01/1995 41 Citations

Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. (Brod SA, Scott M, Burns DK, Phillips JT) J Interferon Cytokine Res 1995 Feb;15(2):115-22 PMID: 8590314 SCOPUS ID: 2-s2.0-0028964995 02/01/1995 38 Citations

Treatment of autoimmune diseases by oral tolerance to autoantigens. (Weiner HL, Miller A, Khoury SJ, Zhang ZJ, al-Sabbagh A, Brod SA, Lider O, Higgins P, Sobel R, Matsui M) Adv Exp Med Biol 1995;371B:1217-23 PMID: 7502787 SCOPUS ID: 2-s2.0-0029133691 01/01/1995 11 Citations

Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. (Brod SA, Burns DK) Neurology 1994 Jun;44(6):1144-8 PMID: 8208413 SCOPUS ID: 2-s2.0-0028236020 06/01/1994 59 Citations

Defective CD3 mediated proliferation and LPS responsiveness in multiple sclerosis. (Brod SA, Scott M) Autoimmunity 1994;17(2):143-8 PMID: 7520286 SCOPUS ID: 2-s2.0-0028304012 01/01/1994 4 Citations

CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. (Freeman GJ, Lombard DB, Gimmi CD, Brod SA, Lee K, Laning JC, Hafler DA, Dorf ME, Gray GS, Reiser H) J Immunol 1992 Dec 15;149(12):3795-801 PMID: 1281186 SCOPUS ID: 2-s2.0-0027057908 12/15/1992 148 Citations

Antigen-driven peripheral immune tolerance. Suppression of organ-specific autoimmune diseases by oral administration of autoantigens. (Weiner HL, Zhang ZJ, Khoury SJ, Miller A, al-Sabbagh A, Brod SA, Lider O, Higgins P, Sobel R, Nussenblatt RB) Ann N Y Acad Sci 1991 Dec 30;636:227-32 PMID: 1793212 SCOPUS ID: 2-s2.0-0026408909 12/30/1991 21 Citations

Restricted T cell expression of IL-2/IFN-gamma mRNA in human inflammatory disease. (Brod SA, Benjamin D, Hafler DA) J Immunol 1991 Aug 01;147(3):810-5 PMID: 1907306 SCOPUS ID: 2-s2.0-0025820259 08/01/1991 79 Citations

Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the Lewis rat and strain 13 guinea pig. (Brod SA, al-Sabbagh A, Sobel RA, Hafler DA, Weiner HL) Ann Neurol 1991 Jun;29(6):615-22 PMID: 1716432 SCOPUS ID: 2-s2.0-0025753324 06/01/1991 61 Citations

Common T-cell receptor V beta usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. (Lee SJ, Wucherpfennig KW, Brod SA, Benjamin D, Weiner HL, Hafler DA) Ann Neurol 1991 Jan;29(1):33-40 PMID: 1847614 SCOPUS ID: 2-s2.0-0026085730 01/01/1991 58 Citations

Reply (Hafler DA, Wucherpfennig KW, Brod SA, Weiner HL) Annals of Neurology October 1991;30(4):624-624 SCOPUS ID: 2-s2.0-84987418683 01/01/1991

T-T cell interactions are mediated by adhesion molecules. (Brod SA, Purvee M, Benjamin D, Hafler DA) Eur J Immunol 1990 Oct;20(10):2259-68 PMID: 1700751 SCOPUS ID: 2-s2.0-0025124143 10/01/1990 41 Citations

Frequency analysis of CD4+CD8+ T cells cloned with IL-4. (Brod SA, Purvee M, Benjamin D, Hafler DA) Cell Immunol 1990 Feb;125(2):426-36 PMID: 2105169 SCOPUS ID: 2-s2.0-0025157213 02/01/1990 23 Citations

Lymphokine regulation of CD45R expression on human T cell clones. (Brod SA, Rudd CE, Purvee M, Hafler DA) J Exp Med 1989 Dec 01;170(6):2147-52 PMID: 2531196 PMCID: PMC2189525 SCOPUS ID: 2-s2.0-0024358131 12/01/1989 58 Citations

Immunoregulation in multiple sclerosis. (Hafler DA, Brod SA, Weiner HL) Res Immunol 1989 Feb;140(2):233-9; discussion 245-8 PMID: 2525796 SCOPUS ID: 2-s2.0-0024517296 02/01/1989 5 Citations

Lack of antibodies to Borrelia burgdorferi in patients with amyotrophic lateral sclerosis. (Mandell H, Steere AC, Reinhardt BN, Yoshinari N, Munsat TL, Brod SA, Clapshaw PA) N Engl J Med 1989 Jan 26;320(4):255-6 PMID: 2911315 SCOPUS ID: 2-s2.0-0024476920 01/26/1989 28 Citations

Primary omphalomesenteric adrenocarcinoma with metastases to the brain. (Brod SA, Spencer SS, Kim JH) Surg Neurol 1988 Jul;30(1):68-70 PMID: 3394013 SCOPUS ID: 2-s2.0-0023820794 07/01/1988

Idiopathic CSF pleocytosis in relapsing polychondritis. (Brod S, Booss J) Neurology 1988 Feb;38(2):322-3 PMID: 3340303 SCOPUS ID: 2-s2.0-0023832920 02/01/1988 28 Citations

Predictors of success for drug discontinuation following neonatal seizures. (Brod SA, Ment LR, Ehrenkranz RA, Bridgers S) Pediatr Neurol 1988 Jan-Feb;4(1):13-7 PMID: 3233103 SCOPUS ID: 2-s2.0-0023856284 01/01/1988 14 Citations

Eye movements, EEG, and fatal anoxic coma (Brod SA, Mattson RH, Ebersole JS) Annals of Neurology January 1988;23(1):101-101 SCOPUS ID: 2-s2.0-84987415537 01/01/1988

Last update: 12/22/2021

© 2022 Clinical & Translational Science Institute
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53223

Publication and ontology data from NCBI | Disclaimer and Copyright

This site is a collaborative effort of the Medical College of Wisconsin and the Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number 8UL1TR000055) at the National Institutes of Health (NIH).

Faculty Collaboration Database

Profiles for MCW, MU, MSOE, UWM, BCW, CW, Froedtert, and VA Faculty

Staley A. Brod MD

Professor

Publications (85)